<div id="readability-page-1"><p>William Blair analyst Myles Minter has reiterated their neutral  stance on <span>MRNA</span> stock, giving a Hold rating today.</p><h3>TipRanks' Prime Week Sale - 70% Off</h3><ul><li> Unlock powerful  investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.</li><li> Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.</li></ul> <p>Myles Minter has given his Hold rating due to a combination of factors that balance Moderna’s strong platform with its execution risks. He views the company’s mRNA technology and manufacturing capabilities as industry-leading, with clear advantages in cost efficiency and the ability to design complex, multiplexed products across oncology and autoimmune indications.</p> <p>At the same time, much of the value lies in early-stage programs that still need to mature clinically, which tempers near-term visibility and justifies a more neutral stance. While management’s disciplined capital allocation and faster-than-expected cost reductions are encouraging, the dependence on proof-of-concept success from “sentinel” assets and subsequent expansion introduces uncertainty that, in his view, warrants maintaining a Hold rather than a more aggressive rating.</p> <p>In another report released today, Citi also maintained a Hold rating on the stock with a $41.00 price target.</p></div>

MRNA

MRNX

MRNY

<p>William Blair analyst Myles Minter reiterated a Hold rating on Moderna (MRNA), citing its industry-leading mRNA platform balanced against early-stage pipeline risks. While acknowledging strong manufacturing capabilities and cost efficiencies, the neutral stance reflects uncertainty regarding clinical maturity of key programs. Citi also maintained a Hold rating with a $41 price target.</p>

Tip Ranks

Moderna

Defiance Daily Target 2X Long MRNA ETF

YieldMax MRNA Option Income Strategy ETF

Citigroup

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks